Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
Medico Remedies has secured the order to supply Azithromycin 500gm (tablets) to Uttar Pradesh Medical Supplies Corporation Limited
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
The FDA also noted that current prescribing information for GLP-1 RAs already includes warnings about the risk of suicidal thoughts
Experts caution that realizing AI’s potential requires careful management and risk mitigation
Subscribe To Our Newsletter & Stay Updated